全国范围内加强胰腺癌最佳实践实施(PACAP-1):多中心阶梯楔形整群随机对照试验
PACAP-1是一项全国性多中心阶梯楔形整群随机对照优效性试验,旨在评估在荷兰17个胰腺中心及转诊网络中加强实施胰腺癌最佳实践(化疗、胰酶替代、胆道引流)能否改善1年总生存和生活质量。研究主要结局为1年总生存,计划样本量2142例患者,统计效能80%以检测10%死亡率下降。
要点
- 全国性阶梯楔形整群随机设计,覆盖荷兰17个胰腺中心及区域转诊网络。
- 干预措施为实施胰腺癌最佳实践:化疗、胰酶替代治疗和金属胆道支架。
- 主要结局为1年总生存,10%的1年总生存改善被认为具有临床相关性。
核心结论
- PACAP-1试验旨在评估全国性加强实施胰腺癌最佳实践的项目能否改善1年总生存和生活质量。
研究设计与样本
- PACAP-1是一项全国性多中心阶梯楔形整群随机对照优效性试验。
- 干预在17个荷兰胰腺中心及其区域转诊网络中按中心逐一随机、阶梯式实施,启动期为6周。
- 每个胰腺中心有一个多学科团队作为网络中其他中心的参照。
- 研究持续时间25个月,为检测17个胰腺中心10.0%的死亡率下降提供80%统计效能,所需样本量2142例患者。
关键数值与推荐
- 主要结局为1年总生存(涵盖所有疾病分期)。
- 次要结局包括生活质量、3年和5年总生存以及指南依从性。
- 1年总生存改善10%被认为具有临床相关性。
- 样本量2142例患者对应6.6%的死亡率下降,全国范围对应4769例患者。
临床怎么用
- 最佳实践源自文献、荷兰胰腺癌项目(PACAP)现有全国注册数据3年数据及全国专家会议。
- 最佳实践遵循荷兰胰腺癌指南和当前文献,可在日常临床实践中执行。
- 实施过程包括监测、回访、提供者反馈,并结合教育和提醒。
- 患者结局和依从性在PACAP注册系统中监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical practice is often suboptimal. We hypothesized that a nationwide program to enhance implementation of these best practices in pancreatic cancer care would improve survival and quality of life. METHODS/DESIGN: PACAP-1 is a nationwide multicenter stepped-wedge cluster randomized controlled superiority trial. In a per-center stepwise and randomized manner, best practices in pancreatic cancer care regarding the use of (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents are implemented in all 17 Dutch pancreatic centers and their regional referral networks during a 6-week initiation period. Per pancreatic center, one multidisciplinary team functions as reference for the other centers in the network. Key best practices were identified from the literature, 3 years of data from existing nationwide registries within the Dutch Pancreatic Cancer Project (PACAP), and national expert meetings. The best practices follow the Dutch guideline on pancreatic cancer and the current state of the literature, and can be executed within daily clinical practice. The implementation process includes monitoring, return visits, and provider feedback in combination with education and reminders. Patient outcomes and compliance are monitored within the PACAP registries. Primary outcome is 1-year overall survival (for all disease stages). Secondary outcomes include quality of life, 3- and 5-year overall survival, and guideline compliance. An improvement of 10% in 1-year overall survival is considered clinically relevant. A 25-month study duration was chosen, which provides 80% statistical power for a mortality reduction of 10.0% in the 17 pancreatic cancer centers, with a required sample size of 2142 patients, corresponding to a 6.6% mortality reduction and 4769 patients nationwide. DISCUSSION: The PACAP-1 trial is designed to evaluate whether a nationwide program for enhanced implementation of best practices in pancreatic cancer care can improve 1-year overall survival and quality of life. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03513705. Trial opened for accrual on 22th May 2018.
引用
- Mackay TM, Smits FJ, Latenstein AEJ, et al. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial. Trials. 2020. PMID: 32299515. doi:10.1186/s13063-020-4180-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。